Latest Research on Orthoflavivirus Vaccines
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines Against Tropical and Other Infectious Diseases".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 315
Special Issue Editor
Interests: anti-viral immunity; live-attenuated viral vaccine; mouse models of virus infection; humanized mouse models; viral immunogenicity; viral pathogenicity
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue is a continuation of our previous one:
https://www.mdpi.com/journal/vaccines/special_issues/5TX1285H70
Orthoflavivirus is a viral genus of single-stranded positive-sense RNA viruses, which includes several highly clinically relevant viruses, such as dengue virus (DENV), yellow fever virus (YFV), West Nile virus (WNV) and Zika virus (ZIKV). Orthoflaviviruses are commonly transmitted by blood-sucking arthropods (mosquitoes, ticks, etc.) to vertebrates and humans and can cause large-scale outbreaks. Most orthoflaviviruses cause zoonotic diseases that translate into a variety of clinical manifestations, from mild to lethal viscerotropic disease or encephalitis.
The re-emergence of multiple orthoflaviviruses over the past decade, from YFV in Brazil and Angol and ZIKV in the Americas, has been a powerful reminder of the increasing health and economic threats posed by orthoflaviviruses worldwide. Climate change and its consequential impact on global temperatures have been nurturing that threat by expanding the endemic areas of several known orthoflavivirus vectors. The increase in human density and destruction of natural habitats in those endemic areas are also perfect recipes for setting up the stage for the rapid emergence of novel or currently neglected orthoflaviviruses with strong epidemic potential (such as Usutu virus, Ilheus virus, or Wesselsbron virus). Taken together, these concerns call for an urgent need to expand our portfolio of antiviral countermeasures against orthoflaviviruses.
Today, most orthoflavivirus infections remain non-preventable because of the lack of effective vaccines. The only licensed orthoflavivirus vaccines, including those targeting YFV and DENV, rely on live-attenuated platforms. However, these platforms are associated with safety concerns (e.g., unsuitable for immunocompromised individuals and risks of antibody-dependent enhancement) and can be challenging to manufacture in high volumes during public health emergencies. Recent advances in our understanding of orthoflavivirus immunity and vaccine development, including the emergence of new platforms such as RNA-based vaccines and insect-specific flaviviruses, open novel avenues for the design of effective and safe vaccines against a large panel of current and emerging orthoflaviviruses. This Special Issue focuses on the latest research on orthoflavivirus vaccine development. We are interested in original research articles or short communications focusing on anti-orthoflavivirus immunity for guiding the rational development of vaccines, as well as in original translational studies focusing on orthoflavivirus vaccine evaluation and safety. We are also interested in comprehensive or systematic reviews of current and future vaccine approaches against orthoflavivirus-induced diseases. All manuscripts will follow standard journal peer review practices. We look forward to receiving your contributions to the Special Issue.
Dr. Florian Douam
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- orthoflavivirus vaccines
- vaccine development
- dengue virus
- yellow fever virus
- west nile virus
- zika virus
- tick-borne encephalitis virus
- immunization
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
